Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing in biosimilars, and how the current pricing system is putting the sustainability of the Turkish pharma industry in danger.
While scaling our company by uniting with others would make us more competitive on a global scale, we still believe it is possible to be successful with good products and the ability to be flexible and grow as a family business
